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Abstract
Background: Publicly funded biomedical and health research is expected to achieve the best return possible for
taxpayers and for society generally. It is therefore important to know whether such research is more productive if
concentrated into a small number of ‘research groups’ or dispersed across many.
Methods: We undertook a systematic rapid evidence assessment focused on the research question: do economies
of scale and scope exist in biomedical and health research? In other words, is that research more productive per
unit of cost if more of it, or a wider variety of it, is done in one location? We reviewed English language literature
without date restriction to the end of 2014. To help us to classify and understand that literature, we first undertook
a review of econometric literature discussing models for analysing economies of scale and/or scope in research
generally (not limited to biomedical and health research).
Results: We found a large and disparate literature. We reviewed 60 empirical studies of (dis-)economies of scale
and/or scope in biomedical and health research, or in categories of research including or overlapping with
biomedical and health research. This literature is varied in methods and findings. At the level of universities or
research institutes, studies more often point to positive economies of scale than to diseconomies of scale or
constant returns to scale in biomedical and health research. However, all three findings exist in the literature, along
with inverse U-shaped relationships. At the level of individual research units, laboratories or projects, the numbers
of studies are smaller and evidence is mixed. Concerning economies of scope, the literature more often suggests
positive economies of scope than diseconomies, but the picture is again mixed. The effect of varying the scope of
activities by a research group was less often reported than the effect of scale and the results were more mixed.
Conclusions: The absence of predominant findings for or against the existence of economies of scale or scope
implies a continuing need for case by case decisions when distributing research funding, rather than a general
policy either to concentrate funding in a few centres or to disperse it across many.
Keywords: Economies of scale, Economies of scope, Biomedical and health research
Background
Funders typically desire to ensure that support is given
to high quality research in a range of areas and institu-
tions. Private industry has a strong commercial impera-
tive driving its decisions about where to invest its
research and development (R&D) effort and whether to
concentrate that in one or a few research centres or to
spread it around multiple centres. Public funders have to
answer to the people whose funds they are using. It is
therefore important to know whether publicly funded
biomedical and health research is more productive if
concentrated or if dispersed [1, 2].
We wish to know the extent of any economies or dis-
economies of scale or scope, and at what levels of aggre-
gation they arise, to inform decisions on research
funding allocation. Economies of scale exist when the
average cost per unit of a single output is lower the
greater the quantity produced in one place, e.g. the cost
per MRI scan falls as the proportion of time a scanner is
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in use increases. Economies of scope are said to exist
when undertaking two different activities in the same
place leads to greater output per pound spent than
undertaking the same two activities separately, e.g.
researching diagnostics in the same place as researching
medicines. If there are economies of scale and/or scope,
then biomedical and health research funding would pro-
duce more and/or higher quality outputs if undertaken
in centres characterised by a large number of researchers
and/or a variety of research activities. Conversely, if
there are diseconomies of scale and/or scope, then re-
search funding would be more productive if undertaken
in smaller and/or more narrowly focused research cen-
tres. If there are neither economies nor diseconomies of
scale or scope, then research outputs per pound spent
would be unaffected by the quantity and variety of re-
search taking place in any given research centre.
The mechanisms by which economies of scale might
arise in biomedical and health research include the abil-
ity, as the scale of research activity grows, to make more
efficient use of lumpy items of equipment or buildings
or of other fixed costs that are location-specific, such as
ready access to a pool of specialist support staff perform-
ing managerial and administrative functions (finance,
legal, and so on). Diseconomies of scale might arise from
conflicting pressures to use key equipment or specialist
support staff, or from increasing difficulty in coordinating
teams of individuals as those teams grow, or simply from
increased bureaucracy. Economies of scope can be
thought of as the synergies that arise by undertaking dif-
ferent kinds of research side by side. Diseconomies of
scope might arise where the synergies are few but the var-
iety leads to a loss of focus in research efforts. The re-
mainder of this paper concentrates on the prior question
of whether there is any quantitative evidence of the exist-
ence of (dis-)economies of scale and/or scope in biomed-
ical and health research. The studies we have found do
not, in general, quantify the mechanisms that may be
causing those (dis-)economies.
This paper presents the results of a literature review
undertaken to determine the current state of empirical
evidence about (dis-)economies of scale or scope in
studies of publicly funded research. The review was part
of a study undertaken on a grant from the United
Kingdom Medical Research Council. The economics of
R&D in the for-profit life sciences industry is the subject
of substantial literature, the majority of which focuses
on the pharmaceutical industry; see in particular the re-
view by Mestre-Ferrandiz, Sussex and Towse [3]. How-
ever, to our knowledge, the study we report here is the
first review of the literature on the economics of scale and
scope in publicly funded biomedical and health research.
We found empirical evidence about economies of scale
and/or scope in biomedical and health research to be
spread across a disparate literature. Studies varied ac-
cording to the breadth/specificity of the research areas
analysed within biomedical and health research and
whether they included other types of research beyond
that field, the kind of research organisations focused on
(from teams to whole universities), whether the focus
was local or national, whether university teaching was
analysed as another output alongside research, whether
scale or scope or both were investigated, and the eco-
nomic methodology adopted, as well as different geo-
graphical locations and time periods. The literature was
not only disparate but also extensive. We have reviewed
in full 60 empirical research papers and summarise them
here, in addition to 37 economic methodology papers.
Given the large number and variety of the papers we
found, it has not been feasible within the scope of this
project to undertake an analysis of the specific weak-
nesses and strengths of each paper. We hope to be able
to address that in future research. In the remainder of
this paper, we focus on what the numerous empirical
studies imply about the presence or otherwise of econ-
omies of scale and/or scope, and the extent to which the
findings vary systematically according to circumstances.
The results of the review should be of interest to bio-
medical and health research funders and policymakers
internationally.
Methods
We carried out the literature review in two stages; first,
reviewing the general econometric literature to ascertain
what methods are considered appropriate for the empir-
ical investigation of economies of scale and/or scope in
research generally, then reviewing empirical studies of
economies of scale and/or scope in biomedical and
health research.
Review of econometric techniques relevant to economies
of scale and scope in research
Economies of scale and scope have been investigated in
many areas of research activity and a variety of geo-
graphical settings and time periods. In December 2014
and January 2015, we undertook a rapid review of the
recent econometric literature about estimating econ-
omies of scale and scope in research generally. The pur-
pose of this initial review was to understand how
economies of scale and scope in research might be ana-
lysed empirically, including whether there were any new
econometric techniques particularly pertinent to investi-
gating economies of scale and/or scope in research, to
help structure our subsequent literature review in the
area of biomedical and health research, and to enable us
to interpret that literature better.
Given the large volume of econometric literature dis-
cussing economies of scale and/or scope in research
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generally, we focused only on publications from the
most recent 6 years, January 2009 to November 2014, as
listed in the two main databases of economic literature
in the English language: Econlit (through the webpage
EBSCOhost) and RePEc (Research Papers in Economics,
through the webpage IDEAS). We initially searched on
the terms ‘economies’ and ‘research’ and ‘scale’ or ‘scope’,
and then filtered first by reviewing article titles, then ab-
stracts. The exclusion criteria are described below. The
review of the econometric methods articles was per-
formed by one person and was then checked by two
other members of the research team to ensure quality
and consistency.
Analysis of economies of scale and scope has trad-
itionally depended on estimation of total cost. This is
fairly straightforward when analysing the production of
specific goods or services (e.g. computers or insurance),
since the total cost can be estimated as the summation
of the quantities of required inputs to produce a given
unit of output, weighted by the price of each input.
However, when analysing production in research, inputs
are highly differentiated – for example, labour inputs to
research are highly differentiated by the qualifications,
skills, knowledge and experience they embody – and
corresponding input prices are difficult to obtain. Fur-
thermore, since research is a multi-product process, it is
problematic to distinguish how much of which inputs is
responsible for the production of a particular research
output. Consequently, we excluded from further review
those articles that are related to econometric techniques
in which the estimation of total costs is based on the
multiplication of input prices and input quantities.
Traditional methodologies for estimating economies of
scale are based on mono-product processes. However,
the process of production in biomedical and health re-
search is inevitably a multi-product process. As mono-
product methodologies are inadequate for the analysis of
economies of scale and scope in research, we excluded
papers that did not consider a multi-product process.
We ultimately analysed the full texts of 36 papers from
this rapid review.
Review of literature on economies of scale and scope in
biomedical and health research
The findings from the first review helped us to structure
the main review of the literature on economies of scale
and scope in biomedical and health research, and helped
us to interpret that literature. Systematic reviews bring
together previous research on a specific question using a
systematic, methodical research process, a critical ap-
praisal of the evidence, and synthesis of findings. We
undertook a systematic rapid evidence assessment (REA)
focused on the research question: do economies of scale
and scope exist in biomedical and health research? or, in
other words, is it better to support research in the same
place rather than spread support across many places?
We selected a REA methodology owing to the unex-
plored nature of the landscape, we were not aware of
any previous literature reviews covering these questions,
and did not find any subsequently. The REA revealed a
large amount of relevant material (as is explained in
more detail below). REAs follow the same structure as
systematic reviews, and are similarly replicable and
transparent, but are less resource intensive. This is
achieved by formally constraining the types of research
to be searched, the time period, where to find the re-
search, and in what language [4]. To increase the robust-
ness of our search we ‘snowballed’ by inspecting the
references in the papers we found. Moreover, we in-
cluded grey literature as well as peer review journals.
The following search terms were used in the first stage
of the REA literature review:
 “(econom* OR diseconom*) of scale”
 “(econom* OR diseconom*) of scope”
 “scope (econom* OR diseconom*)”
 “scale (econom* OR diseconom*)”
 “co-location” OR colocation OR “co location”
 “research unit*”
 “research centre*” OR “research center*”
 “centre* of excellence” OR “center* of excellence”
 “team size” OR “group size” OR “unit size” OR
“department size” OR “institute size” OR “institution
size” OR “lab size” OR “laboratory size”
 “project team” OR “project team dynamics” OR
“project team*” OR “large project team*” OR “small
project team*”
 “productive efficiency”
 “technical efficiency”
 ((efficienc* OR perform* OR productivity) AND
(scale OR scope))
We performed individual searches of each of the previ-
ous terms in combination with the following criteria:
 “health* research” OR “medical research” OR “bio*
research” OR “life science* research”
For the review of literature on economies of scale and
scope in biomedical and health research we used the da-
tabases: EconLit, ASC, BSC, Cinhal, PubMed, Scopus,
and Web of Science. In this, as in the econometric litera-
ture search, we restricted to articles published in English.
We excluded papers that focused on private sector R&D
only, focused at too high a level, combining multiple dis-
tinct research organisations (e.g. research clusters, re-
search/science parks), and that reviewed a particular
centre in isolation or reported a decision to fund a centre.
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This first stage yielded 4029 hits, which were reduced
to 558 following title filtering and reduced to 212 after
filtering by abstract. Further inspection of the full text
left 23 papers for inclusion in the review (Fig. 1): 15
were identified by the search strategy directly, to which
we added six papers from snowballing from citations in
those 15, and two more from personal knowledge of the
researchers.
We were concerned that two relevant empirical papers
known to one of the authors from previous work had
not been found by the search strategy alone. We there-
fore decided to conduct a second stage literature search
relaxing the search criteria to find any empirical papers
that covered areas of research that included or over-
lapped with biomedical and health research, although
they might not have focused on economies of scale or
scope only in biomedical and health research. To do
this, we removed the restriction represented by the
health research criteria (“health* research” OR “medical
research” OR “bio* research” OR “life science* research”)
and relied on our review and exclusion process to ex-
clude articles with no relevance whatsoever to biomed-
ical and health research. This second stage yielded 4405
additional hits, which we reduced to 187 after title filter-
ing, to 93 after abstract filtering, and to 37 after review-
ing the full text (Fig. 1).
Thus, taken together, the two stages yielded a total
of (23+37=) 60 references that provide information
about economies of scale and/or scope in biomedical
research. These 60 papers are listed in the References
section.
We tested the feasibility of formally and systematically
evaluating the papers by drawing on and adapting two
existing frameworks as suggested by Gough [5], namely
using EPPIs Weight of Evidence Framework and the
TAPUPAS dimensions [6]. However, the wide variety of
methodologies and approaches found in the literature
hinder comparison of the quality of the articles.
Several of the papers analyse higher education institu-
tions as producers of research, postgraduate teaching
and undergraduate teaching, rather than focusing on dif-
ferent types of research alone. As they, in part, address
the issue of economies of scale in research, including
biomedical and health research, these papers are in-
cluded in our analysis.
Results and discussion
Econometric techniques for estimating economies of
scale and scope
The literature suggests three main groups of economet-
ric approaches to estimating economies of scale and/or
scope. Table 1 shows the 36 articles included in the
econometric literature review according to the econo-
metric methodology used. The category called ‘Others’
represents those publications whose methodology can-
not be grouped.
Proxy variables
The first group of methodologies analyses economies of
scale and/or scope by using proxies for the scale and for
the scope of the research group, respectively. Variables
such as total number of innovation projects in a research
group, total number of projects started by the firm, total
number of ongoing projects for the research group at a
point in time, and total numbers of students enrolled (in
the analysis of scale at higher education institutions),
have been used as proxies for research group scale. In
some articles, more than one proxy is used, namely one
that reflects the scale of the whole research group and
another that reflects the scale of the specific unit within
the research group, e.g. the size of the research team.
Scope is addressed by using proxies such as thematic
concentration of an institution in a specific output,
entropy of the uniformity of the distribution of differ-
ent projects within a research group portfolio, or a
Herfindahl index of the diversity of projects in a re-
search group [7–9]. The research group’s Herfindahl
index is defined as:
HI ¼
XN
i¼1s
2
i ð1Þ
and the entropy of the distribution of projects is esti-
mated as:
Entropy ¼ −
XN
i
siln sið Þ ð2Þ
where si is the share of projects in indication i as
part of the total number of projects (taking projects
Fig. 1 Search results
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as a quantitative measure of research group output)
undertaken by the research group, and N is the num-
ber of indications. Thus, in a research group that has
equal numbers of projects in two indications, the
Herfindahl index equals 0.52+0.52 = 0.5 and the entropy is
equal to –(0.5*ln(0.5)+0.5*ln(0.5)) = 0.69. While a research
group that has equal numbers of projects in each of three
different indications has a Herfindahl index equal to 0.33
and an entropy equal to 1.10. The smaller the Herfindahl
index, or the greater the entropy, the greater is the re-
search group’s assumed scope.
After the selection of a proxy to measure the scale or
scope, the relationship between the proxy variable and
the output level is analysed. For instance:
Y i ¼ αþ β1ScaleProxy1 þ β2ScaleProxy2
þ β3ScopeProxyþ
Xk
l¼1δlXl þ ε ð3Þ
Where Yi is the total production of output i (i = 0,…,N),
α, β1, β2, β3 and δl are parameters to be estimated, Xl cor-
responds to a set of independent variables, and ε is the
error term. Depending on the characteristics of the data-
bases used and the interests of the authors, a variety of
standard econometric techniques have been applied in the
literature to estimate this type of equation, e.g. ordinary
least squares [8, 10], random effects model [11], probit [7],
structural [7], and logit models [9].
Multi-product cost functions
The methodology of the second group of articles
(Table 1) is based on the analysis of the multi-product
cost function. The specification of this cost function was
originally proposed by Baumol et al. [12]. In particular,
the quadratic functional form of the multi-product cost
function is estimated. Here, the total cost of producing
N different outputs is dependent on the level of produc-
tion of each of the outputs and on a group of control
variables, as follows:
TCN ¼ αþ
XN
i¼1βiY i þ
XN
i¼1
XN
j¼1βijY iY j
þ
Xk
l¼1δlXl þ ε ð4Þ
Where Yi are the output variables, TCN is the total cost
of producing all outputs, ε is again the error term, Xl are
control variables, and the other terms are coefficients to
be estimated.
In this methodology, two types of economy of scale in
a multi-product process are addressed, namely ray econ-
omies of scale and product-specific economies of scale.
Ray economies of scale are the impact on cost resulting
from an increase in the production of all types of output
by the same proportion. Product-specific economies of
scale are the impact on cost of increasing the production
of only one of the outputs while keeping production of
all other outputs unchanged. Thus:
Ray economy of scale ¼ TCN=
XN
i¼1MarginalCosti  Y i
h i
ð5Þ
Product specific economy of scale
¼ TCN−TCN−i½ = MarginalCosti  Y i½  ð6Þ
Where TCN − i is the total cost of producing all out-
puts but Yi.
The ray economy of scale, equation (5), is the ratio be-
tween the total costs of producing all outputs together
and the sum of the outputs weighted by their marginal
costs. If the total cost is higher than the sum of the
Table 1 Classification of articles on econometric techniques to estimate economies of scale and/or scope
Econometric technique to estimate economies of scale
and/or scope
Articles
Group 1. Through the selection of proxy variables Arora et al. [7], Brahm & Tarziján [8], De & Nagaraj [11], Horta & Lacy [56], Plotnikova [9],
Qin & Buccola [57], Shakina & Barajas [10]
Group 2. Analysis of multi-product cost functions Agasisti & Johnes [14], Duch-Brown & Parellada-Sabata [18], Fu et al. [58], Johnes &
Johnes [15], Johnes & Schwarzenberger [16], Longlong et al. [59], Mamun [19],
Martins et al. [20], Sav [17], Sav [13], Worthington & Higgs [60]
Group 3. Analysis of multi-product production functions Bonaccorsi et al. [27], Cardamone [28], Chavas et al. [21], De Witte et al. [26],
Ferrier et al. [24], Ferrier et al. [25], Hadad et al. [29], Podinovski & Førsund [30],
Pope & Johnson [23], Ray [61], Schubert [22], Yip et al. [62]
Others Cho & McCardle [63] (discrete-time infinite-horizon model for a
technology-purchasing firm),
Mayer-Haug et al. [64] (meta-analysis)
Nemoto & Furumatsu [65] (input distance function approach)
Olivares & Wetzel [51], Oh et al. [66] (comparison between a parametric production
function approach and a nonparametric approach)
Saal et al. [67] (summary of various methodologies)
Source: Authors’ elaboration
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marginal costs, an increase in the whole level of produc-
tion across the board will increase the total cost less
than proportionally. Therefore, if the resulted value from
equation (5) is higher than the unity, there remain some
untapped economies of scale.
Product-specific economies of scale are measured
through the ratio between the difference in the cost of a
production process with and without the output i and
the production of Yi alone weighted by its marginal cost
(equation (6)). Again, a value higher than unity means
that there is an untapped economy of scale in the pro-
duction of output Yi.
The concept of economies of scope differs from the
previous two concepts in that what is important is not
so much the size of the research group, but the mix of
products. Methodologies that are based on the multi-
product cost function analyse economies of scope
through the ratio between the total cost of producing
output Yi in one firm and all other outputs separately in
another firm (TCi + TCN − i), with the total cost of pro-
ducing all outputs within one firm (TCN), as shown in
the following equation:
Economiesof scope ¼ TCi þ TCN−i−TCN½ =TCN
ð7Þ
In this case, values higher than zero indicate that
economies of scope exist.
Equations (5), (6) and (7) are based on the estimation
of equation (4), which can be done using a variety of
econometric techniques. Depending on the data avail-
able and the interest of the authors, different economet-
ric techniques have been used, for instance, panel data
fixed effects [13], random parameter model [14–16], or-
dinary least squares [17], Generalized Least Squares [18],
random parameter Stochastic Frontier models [19], and
maximum likelihood technique [20].
Multi-product production functions
In this group of papers (Table 1), the analysis is based
on the idea, and estimation, of a production frontier, i.e.
the maximum quantities of outputs that can be
produced from given inputs in an efficient firm. The
methodologies used in this group are mostly non-
parametric approaches, the specifications of which vary
considerably.
One type of approach compares the production fron-
tier of a situation in which a single firm produces all of
two different outputs by employing all the available in-
puts, with the production frontier where the inputs are
split across more than one firm, each with different
levels of specialisation in the production of output 1 and
output 2 [21]; Fig. 2 illustrates this case. The idea is to
compare the distance between Production Frontier 1,
in which one firm has all the inputs available, and
Production Frontier 2, in which the inputs are divided
between different firms. Production Frontier 2 is the
sum of the production of each firm. In Fig. 2, this
hypothetical case shows an example where economies
of scale exist for all mixes of the two outputs A and
B – the single firm can out-produce multiple firms
using the same total of inputs whatever ratio of out-
put A to output B is desired. The shape of the curve
in this example implies also that there are economies
of scope, namely multiple firms where each firm produces
either output A or output B, but not both, could only
achieve a combined output along the line AB, which is al-
ways below Production Frontier 2 when non-zero quan-
tities of both products are to be produced.
Another approach related to the production frontier
analyses the curvature of the production function [22].
Figure 3 shows a production function in which, at lower
levels of production, the firm faces increasing returns to
scale (the convex part of the curve) and, at higher levels,
it faces decreasing return to scale (the concave part of
the curve).
There are a variety of methodologies for determining
the curvature of the production function for different
groups of firms, including a Free Disposal Hull [22, 23],
Free Coordination Hull [24, 25], a ‘benefit-of-the-doubt’
approach [26], g or a Data Envelopment Analysis (DEA)
[21–23, 27–30]. Curves can be entirely concave, or con-
vex, or constant, or a combination of all three as shown
in Fig. 3. In addition, the position of each firm along the
curve is determined, such that the firm could be located
in the concave or the convex part of the production
frontier. Based on both the form of the curve and the
position of the firm, it is possible to conclude whether
the firm is benefitting from economies of scale.
Fig. 2 Production frontier with two outputs
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Evidence about economies of scale and scope in
biomedical and health research
In principle, economies of scale and/or scope in biomed-
ical and health research could come from two main
sources. They could result from infrastructure, such as
expensive research equipment or costly-to-acquire skills
or support services (legal, financial, managerial, adminis-
tration) that can be provided more cost effectively where
a large group of people are making use of that infra-
structure and are in the same location. Or they could re-
sult from the interactions between researchers, enabling
them to work together better and draw on advice from
colleagues. Diseconomies of scale and/or scope might
result from growing difficulties of coordination when re-
search groups employ larger numbers of people or wider
varieties of different kinds of researchers (with different
expertise and interests and ways of working). The quan-
titative analyses we found did not attempt to identify the
relative importance of the possible sources of any econ-
omies or diseconomies that were detected.
We found 60 papers from the literature review dis-
cussing, in at least part of their content, whether there
exist economies of scale, or economies of scope, or both,
in publicly funded biomedical and health research.
Table 2 shows which of the 60 papers concerned econ-
omies of scale, which concerned economies of scope,
Table 2 Articles included in the literature review
Quantitative Qualitative/Literature Reviews Mixed Methods
Analyses of economies of
scale only
Adams & Griliches [39], Bauer et al. [34],
Bonaccorsi & Daraio [68], Bonaccorsi &
Daraio [38], Bordons & Zulueta [69],
Bordons et al. [70], Cohen [71],
Cohen [72], Gomes et al. [73],
Heale et al. [35], Hoare [43], Johnes &
Johnes [74], Kenna & Berche [33],
Kenna & Berche [44], King [50],
Kretschmer [32], Mamun [75],
Nag et al. [76], Rey-Rocha et al. [77],
Sav [36], Schubert [22], Stankiewicz [78]
Cohen [79], Heinze et al. [80],
Johnston [81], Rhoten [40],
Stokols et al. [82]
von Tunzelmann et al. [85]
(This is a pure theoretical analysis)
Adams et al. [83],
Carayol & Matt [84]
Lowry et al. [86]
Analyses of economies of
scope only
Cherchye et al. [54], Glass et al. [55]
Analyses of both economies
of scale and economies of
scope
Agasisti & Johnes [14], Chavas et al. [21],
Cohn et al. [46], de Groot et al. [48],
Dundar & Lewis [52], Foltz et al. [41],
Glass et al. [45], Hinze et al. [53],
Johnes & Johnes [15], Johnes &
Salas-Velasco [87], Johnes &
Schwarzenberger [16], Laband &
Lentz [47], Mamun [19], Olivares &
Wetzel [51], Olson [88], Sav [37],
Seglen & Aksnes [89], Spanos &
Vonortas [31], Wolszczak-Derlacz &
Parteka [49]
Vonortas et al. [90]
Analyses of topics closely
related to economies of scale
or scope (e.g. co-location)
Abramovsky et al. [91] (effect of
co-location, R&D labs and university)
Atkinson et al. [92] (change in
scientific collaboration along time)
Beise & Stahl [93]
(effect of co-location
(private and public))
Antonio-García et al. [94] (analysed the
effect of size through the satisfaction
with resources)
Bos et al. [95] (co-location of the
team members)
Chin-Tsai & Chang-Tzu [96]
(how research performance
can be assessed)
Coen et al. [97] (integrating the
tangible and intangible structures
that underlie research centre
functioning (co-location))
Source: Authors’ elaboration
Fig. 3 Curvature of the production function
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and which concerned both scale and scope. Seven of the
60 papers included discussion of factors affecting the
productivity of biomedical and health research, particu-
larly the effect of co-location of researchers, but con-
tained no empirical analysis of economies of scale or
scope (last row of Table 2). Of the other 53 papers, 31
look only at economies of scale, two look only at econ-
omies of scope, and 20 cover both scale and scope
(Table 2). Thus, scale was frequently analysed independ-
ently of scope, but scope was seldom analysed in isola-
tion. Methodological approaches are for the most part
quantitative, with only a few cases of qualitative, litera-
ture reviews and mixed methods studies (Table 2).
In the following sections we set out the findings of
these papers in more detail, considering in turn econ-
omies of scale and then economies of scope.
Economies of scale in biomedical and health research
The results of the 51 papers evaluating economies or
diseconomies of scale in biomedical and health research
or in other types of research that include or overlap with
biomedical and health research (listed in rows 1 and 3 of
Table 2), are far from uniform, although positive econ-
omies of scale are found more often than diseconomies
of scale. Table 3 summarises the findings from these 51
papers. Forty-two of the 51 papers offer in essence a sin-
gle overall conclusion about (dis-)economies of scale in
biomedical and health research (or offered no clear conclu-
sion on this point). The other nine of the 51 studies were
designed to be able to identify (dis-)economies of scale in a
number of separate situations and all of them found differ-
ent results according to the situation of interest.
There is no dominant overall conclusion; both econ-
omies and diseconomies of scale are reported in the lit-
erature. Rather more papers report positive economies
of scale (15/42) than report diseconomies (9/42) or
constant returns to scale (7/42). Three papers find that,
while there are positive economies initially as scale in-
creases, these eventually turn to diseconomies after a
certain scale is reached. Spanos and Vonortas [31] detect
economies of scale, measured as the number of partners
in European research projects, up to 25 such partners
but diseconomies of scale thereafter. While Kretschmer
[32] found that diseconomies might set in for research
group sizes above 6–12 members, Kenna and Berche
[33] suggested the turning point might be around 41
group members for medical sciences, 21 for biology and
11 for economics and statistics.
The empirical literature includes studies that focus on
a variety of levels of aggregation of research groups,
from individual research projects under a principal in-
vestigator to whole universities or large research insti-
tutes. In Table 3, the results are broken down according
to the types of ‘research group’ studied. We use the term
‘research group’ to apply to any team of people working
together on research, or to an agglomeration of such
teams. We have defined four ‘research group’ types ac-
cording to the type of unit whose productivity is being
analysed in a study. For instance, those papers classified
under ‘University/Research Institute’ are analysing differ-
ences in productivity between universities and/or re-
search institutes. Productivity might be measured, for
example, as the total number of publications from each
university/institute in a particular period of time, while
the scale measure could be the average size of the re-
search teams within the university/institute. Similarly, in
the case of the ‘Individual level (principal investigator)’
category, those studies are measuring the productivity of
a particular principal investigator while the scale meas-
ure could be the size of their research team.
Among the 51 papers studying economies of scale, six
present analyses in which the unit explored is the
Table 3 Numbers of papers finding (dis-)economies of scale in biomedical and health research – by type of research group whose
productivity is being analysed
Individual level
(Principal Investigator)
Research
Teama
Departmentb University/Research
Institute
Other Total
Diminishing returns to scale/Diseconomies of scale 2 3 1 3 – 9
Increasing returns to scale/Economies of scale 1 3 2 9 – 15
Constant returns to scale 1 3 1 – 2 7
Inverse U-shape – 2 – 1 – 3
Not clear 2 1 3 – 2 8
Sub-total 6 12 7 13 4 42
Articles that suggest both diseconomies and economies of scale
Multi-product cost functions applied – – – 4 – 4
Other methodology applied – 1 – 4 – 5
Total 6 13 7 21 4 51
aResearch Team = Sub-departmental laboratory/research unit
bUniversity department or research centre inside a bigger organisation. A department is typically composed of a number of research teams
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researcher (Table 3). The number of studies in this cat-
egory is small and reveals a spread of findings across all
of decreasing, constant or increasing returns to scale. In
these six studies, neither multi-product cost functions
nor multi-product production functions were used.
Bauer et al. [34] predict the number of publications per
researcher as a function of academic status, sex, depart-
ment size, and quota of senior researchers, and they pre-
dict the number of citations by publication count, status,
department size, and quota of senior researchers. Simi-
larly, Heale et al. [35], using information on publications
and funding per individual principal investigator, analyse
the determinants of scientific knowledge output in bio-
medical research. They find diminishing returns in rela-
tion to the amount of funding available and that a
reasonably stable network of external collaborators is
key for high productivity.
The 13 studies focused at the ‘Research Team’ and the
seven studies focused at the ‘Department’ (sub-university/
institute) level reveal a similar spread of results across
decreasing, constant and increasing returns to scale
(Table 3).
Whole universities or research institutes were the
focus in 21 of the 51 studies looking at economies of
scale. At that level, nine out of 21 papers show positive
economies of scale in research, compared with just three
finding diseconomies of scale. For instance, Sav [36], by
applying DEA, found that “productivity regress was ac-
companied by decreasing returns to scale that prevailed
among more than half of the USA universities”. Nine
other studies focused at the university/research institute
level find a mixed picture with both increasing and de-
creasing returns evident in different circumstances.
We focus now specifically on the nine articles studying
economies of scale that suggest the existence of both
economies and diseconomies of scale, depending on the
specific context (Table 3). Four of these nine articles
used a multi-product cost function approach and esti-
mated both ray economies of scale and product-spe-
cific economies of scale [15, 16, 19, 37]. Johnes and
Schwarzenberger [16] used panel data that allowed the es-
timation of a random parameter stochastic frontier model,
meaning that parameters could vary across institutions.
Based on this methodology the authors found product-
specific economies of scale for research in German univer-
sities (i.e. where research activity increases but teaching
activity remains unchanged the average cost of the re-
search falls) but minimal ray diseconomies of scale (i.e.
when research and teaching increase by the same propor-
tion, average costs of both rise slightly).
Two of the nine articles use DEA analysis [21, 38]. In
these cases, for each university/institute analysed, a dif-
ferent measure of economies of scale is estimated, and
some of the institutions show diseconomies while others
show economies of scale. For instance, of 52 American
universities analysed by Chavas et al. [21], 69% (36/52)
showed economies of scale and 31% (16/52) disecon-
omies. The findings of Bonaccorsi and Daraio [38] sug-
gest diseconomies of scale in the French university
system and a U-shape pattern (diseconomies in smaller
and economies in bigger research institutes) in the case
of Italian universities.
Two other articles from these nine applied different
proxy variables for scale and estimated more than one
equation, and found different views of (dis-)economies
of scale according to which proxy for research output
was used. For instance, Adams and Griliches [39] found
diseconomies of scale in the production of research pub-
lications but positive economies of scale in citations.
Finally, the qualitative analysis by Rhoten [40] indi-
cates that an increase in centre size from small to
medium could increase the number of information shar-
ing ties but not knowledge creating ties, while an in-
crease from medium to large does not appear to
increase either of the two and so would not imply econ-
omies of scale over that range.
Taken as a whole across the group of 51 articles look-
ing at economies of scale, number of publications was
the most common proxy measure of research output
used – in 26 of the 51 papers – reflecting the compara-
tively ready availability of publication counts. Patents
were used as an output measure in just two papers
[21, 41, 42]. Out of the 26 articles based on publica-
tion counts, two included international publications
and 10 consider only publications in indexes of refer-
eed journals. Moreover, 11 of the 26 articles took into
account the quality of the publications through the
numbers of citations.
An additional proxy measure of research output used
in the literature is the quality of research, which applied
in four of the 51 articles and was measured using results
from the United Kingdom’s Research Assessment Exercise
(RAE). The RAE classified university research teams into
five quality levels by means of peer review [33, 43–45].
Numbers of students (postgraduate and undergraduate
usually counted separately) were also quite frequently
used as output of the work of a university or depart-
ment, alongside research. For instance, Mamun [19] in-
cludes as output measures the full-time equivalent
undergraduate students and the full-time equivalent
masters (MPhil) and PhD students. He also included the
research expenditure level as an approximation of the
research output. In this case, ray economies of scale
were found for the totality of outputs while research and
undergraduate teaching show product-specific disecon-
omies of scale. Postgraduate student numbers are argu-
ably a weak proxy for research output. They may be
correlated with research but that correlation might be
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negative or positive – negative because time spent teach-
ing students is time not spent researching and positive
because larger universities, viewed as multi-product
firms, may produce both more teaching and more re-
search. Numbers of PhD students may alternatively be
seen as an indicator of the scale of inputs to the research
process, rather than of the outputs from it. So the use of
student numbers as an output is problematic when try-
ing to assess (dis-)economies of scale, or scope, in
research.
The extent of grants and other external research fund-
ing obtained was used as a proxy for the scale of re-
search output in 11 of the 51 papers. From the
perspective of the recipient research group, the ability to
win external funding is an indicator of success, but that
funding is an input to the research process rather than
an output from it when viewed from a societal perspec-
tive. When comparing two research groups, A and B, if
A wins more research funding than B, we know that it is
using more inputs than B but we do not know if that
greater funding is being turned into proportionally more
or less research output unless we have another proxy
measure for output.
Results by type of model used
As shown in Table 2 (second and fourth columns), of
the 51 articles found that studied economies of scale
(either or alone or along with economies of scope), 45
applied a quantitative (41) or mixed (4) methodology for
the analysis of economies of scale. We have classified
them according to the three main types of models for
assessing economies of scale and/or scope found in our
review of the general econometric literature, and found
20 articles did so through selection of proxy variables,
13 through multi-product cost functions, 7 through
multi-product production functions, and 5 where the
method was unclear or other quantitative approaches
had been used.
Among the 20 papers based on the proxy variables ap-
proach, the findings were varied – two found positive
economies of scale, four found diseconomies of scale,
five found constant returns to scale, three found evi-
dence of both economies and diseconomies of scale, and
three cases showed no clear results. The results of the
remaining three cases indicate an inverse U-shaped rela-
tionship between scale and productivity of research – as
research group size increases, there are positive econ-
omies of scale initially, but eventually they cease and fur-
ther increases in scale are then associated with
diseconomies. For example, Spanos and Vonortas [31]
found an inverse U-shape between number of partners
and networking impacts and a U-shaped effect of budget
on goal achievement. They measure networking impacts
thorough a construct that reflects strengthening links
with other research organisations/businesses and dis-
semination of research results, while goal achievement is
measured through three Likert-type scales of the degree
to which the project achieved its scientific, technical and
commercial objectives. Spanos and Vonortas [31] found
that, with a budget around €1,795,000, the expected
value of goal achievement reaches its minimum level,
and that networking impacts achieve a maximum point
around 24.5 partners. They conclude that the effect of
the scale is curvilinear, meaning that, at high levels of
scale, the positive returns will begin to diminish. Kenna
and Berche [44] find an inverse U-shape between re-
search quality (measured through the RAE) and the
number of researchers in the group. They identify two
critical masses, a lower limit, which is the minimum
number of researchers needed to ensure stability in the
team, and an upper limit after which a greater number
of members increasingly obstructs meaningful commu-
nication and negatively affects the quality of research.
Kenna and Berche [44] suggest that these upper and
lower limits depend on the field of research; for instance,
they found an upper limit for the number of individuals
in a research group equal to 41 (±8) for medical science,
21(±4) for biology and 11 (±3) for economics and
statistics.
Additionally, 13 articles are based on analysis of multi-
product cost functions. Two of these studies found dis-
economies of scale and seven found positive economies
of scale. It is worth mentioning that the results pre-
sented by Cohn et al. [46] have been classified as evi-
dence of positive economies of scale overall, even
though, for private universities, the product-specific in-
dicator shows diseconomies of scale in research. This is
because the results for the more numerous (and larger
on average) public universities show product-specific
economies of scale and, moreover, global (ray) econ-
omies of scale were found in both public and private
universities [46].
The other four of the 13 multi-product cost function
articles show a clear difference between the ray econ-
omies of scale indicator and the product-specific indica-
tors. Three of them suggest the existence of global (ray)
diseconomies of scale together with positive product-
specific economies of scale. However, Mamun [19] finds
the opposite in the case of public universities in a low-
income economy, Bangladesh, namely, that there are
positive global (ray) economies of scale but product-
specific diseconomies of scale for the output ‘research’.
However, as research output is measured by research ex-
penditure (which is a measure of inputs, when seen from
a societal perspective), it is difficult to interpret this
result.
It is also worth noting that all of the 13 multi-
product cost function studies use numbers of students
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(undergraduate and postgraduate students separately)
alongside a measure of research as the outputs of
universities/institutes of higher education. Eight out
of the 13 articles use ‘grants and other research funding/
research expenditures’ as a measure of research output
and four use the number of publications. For instance,
Laband and Lentz [47] based the estimation of the multi-
cost product function on three outputs, (1) the total sum
of the federal, state, local and private research grants in
millions of dollars, (2) the total number of undergraduate
students enrolled in the institution, and (3) the total num-
ber of postgraduate students. They found that private as
well as public universities are characterised by ray econ-
omies of scale and product-specific economies of scale in
research and undergraduate education. Patents are used
as a research output measure by Foltz et al. [41] and the
quality of the research (as measured by the RAE) is used
as an output measure by Glass et al. [45].
An important part of multi-product cost function esti-
mation is the choice of control variables used. A com-
mon practice is to include academic wages (e.g. average
faculty salary) as a proxy for the level of input prices
[19, 37, 41, 46, 47]. Likewise, and given the particu-
larly high costs of a medical department, some studies
include a dummy variable for those universities or institu-
tions that include a medical school [14, 37, 41, 48].
Regarding the seven articles that were based on ana-
lysis of multi-product production functions, five use
DEA [21, 22, 36, 38, 49]. A particular case in this group
is the study conducted by Wolszczak-Derlacz and
Parteka [49], who analysed 259 European universities.
They estimated first the efficiency levels of the univer-
sities using DEA and then, in a second step, they
regressed these efficiency levels on a group of covariates.
Among the covariates they included the number of dif-
ferent faculties. Their findings suggest that a university
with a higher number of different faculties is more effi-
cient. They consider this result as a possible signal of
both economies of scope and economies of scale. An-
other example is the study by Chavas et al. [21], who
broke down the economies of scope effects into three
different parts (complementary, convexity and econ-
omies of scale effects). They found that the scale effect
is particularly important for the small United States re-
search universities. Only one [22] out of the five articles
that applied DEA has a unit of analysis different from
the university. He analysed German research groups
from three scientific fields and found that the efficiency
curve estimated by DEA shows increasing returns to
scale and constant returns to scale. The two articles
that do not use DEA are King [50], who applied a
multi-input multi-output model, and Olivares and
Wetzel [51], who used an input distance function
approach.
Types of biomedical and health research
It might be expected that the likelihood of economies or
diseconomies of scale might differ according to the par-
ticular type of biomedical and health research that is be-
ing conducted. However, the studies we found provide
no basis for drawing conclusions about different sub-
headings of research within ‘biomedical and health’ such
as basic research versus clinical research, or pharmaceut-
ical versus non-pharmaceutical. Most studies looked at
research at a high level of aggregation.
Countries studied
The majority of the studies that analysed economies of
scale (33/51) took an individual country as the focus of
analysis and most of the rest studied two or more coun-
tries internationally. There were few purely sub-national
analyses – six of the papers focused on local level ana-
lyses of individual research institutes or departments
and it was at this level that diseconomies of scale were
most likely to be identified (3/6), whereas positive econ-
omies of scale were found just once, constant returns to
scale were found once and no clear result was found
once. Kretschmer [32] analysed research activity in mo-
lecular biology by some 450 scientists in 56 research
groups, but the source of data and the country to which
the analysis refers are not clearly stated in the paper.
Most of the papers we reviewed in detail looked at re-
search in one or more countries in Europe (24/51) or
North America (16/51) or both (3/51). The remaining
eight studies were either multinational beyond those re-
gions or concerned individual countries in other regions
(e.g. Taiwan), with the exception of Kretschmer [32], in
which it was not possible to identify the country conclu-
sively. Once we exclude those articles whose results indi-
cate both economies and diseconomies of scale, the
remaining 43 articles show a pattern of a slightly higher
probability of finding economies of scale than disecon-
omies of scale regardless of geography.
Summary of findings about economies of scale
In summary, the empirical literature is varied both in
method and findings, but taken as a whole, implies a
greater likelihood of finding positive economies of scale
in biomedical and health research than diseconomies, or
constant returns to scale, although all three kinds of
findings are common. This literature is largely focused
at the whole-university or whole-institute level and usu-
ally takes a national perspective. Results differ across the
wide range of institutions analysed as well as the outputs
selected. Taken together, the literature does not permit
conclusions to be drawn about different kinds of re-
search within the overall heading of biomedical and
health research.
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Economies of scope in biomedical and health research
Having discussed economies of scale we now turn to
economies of scope. We found 22 papers that pre-
sented evidence on (dis-)economies of scope in bio-
medical and health research. Nearly half of these
studies (10/22) found evidence of positive economies
of scope. In other words, they found that the total
cost of producing multiple research outputs in one
place would be lower than the total cost of producing
the same volume and mix of outputs in multiple
places with each place only concentrating on a single
type of output. However, five of the 22 studies found
evidence of diseconomies of scope – implying that it
would be more efficient to concentrate research in
any one place on a narrower range. The remaining
seven studies found evidence of both economies and
diseconomies of scope in research (Table 4).
Studies of economies of scope were most commonly
focused at the level of whole universities or research in-
stitutes (17/22) (Table 4). Seven of the 17 papers analys-
ing at this level found positive economies of scope in
research, but four found diseconomies of scope and the
other six showed evidence for both economies and dis-
economies. Thus, overall, there is no dominant picture
emerging at this level of research group. There were only
three studies focused at the level of departments within
universities and institutes, and taken together they
present mixed results – one study finding economies of
scope [52], one finding diseconomies [53] and one find-
ing evidence for both [54]. The two studies focused at
the ‘Research team’ level support economies of scope at
that level.
Twenty of the 22 studies looking at scope had also
assessed economies of scale. Consequently, it is no sur-
prise that the same range of measures of research out-
puts was evident in studies of scope as in studies of
scale. However, when scope was analysed, it was less
common for publications to have been used to measure
research output. Whereas half of the papers analysing
economies of scale (26/51) had included publications as
an output, a slightly smaller proportion (9/22) of papers
looking at economies of scope did so, two of which con-
sidered citations. Contrastingly, 15 of the studies that in-
cluded scope in their analysis used postgraduate and
undergraduate student numbers, separately, as outputs.
Nine of the times when student numbers were among
the outputs (and not on any other occasions), the
amount of research funding raised was also included as
an output, on the basis that more productive research
groups will attract more funding. Postgraduate student
numbers, specifically PhDs and other research-based de-
grees, might justifiably be seen as research (plus teach-
ing) outputs, though undergraduate student numbers
are a proxy for teaching output alone. However, PhD
students are also an input to research, as well as a partial
proxy for output. Grants and other external funding re-
ceived are inputs to biomedical and health research as
well as outputs from it, so the direction of causation
runs both ways.
Although they are crude measures, and are far from
representing the full fruits of biomedical and health re-
search, counts of publications and patents are at least
outputs from research, and are arguably even better
proxies if quality-adjusted in some way. Nine of the 22
studies of economies of scope used publications as their
measure of research output, and two of those also used
patents (no study used patents without also using publi-
cations as a research output). The two studies using both
publications and patents as outputs were those of
Chavas et al. [21] and Foltz et al. [41], both of which are of
United States universities and found significant economies
of scope in producing publications and patents. Foltz et al.
[41] estimated two regressions, one using only quantitative
output measures and another adjusting the quantity of ar-
ticles and patents according to their quality by considering
the number of citations. Significant evidence of economies
of scope was found only for the case in which the outputs
where adjusted by the number of citations.
The nine studies where publications, alone or with
patents, were used as a measure of research output were
more likely than the others to show the presence of
positive economies of scope – six of the nine did so
(including both papers that also used patents as a re-
search output), compared with two showing disecon-
omies of scope, and one showing evidence of both
economies and diseconomies of scope.
Of the 13 (out of 22) studies of scope that did not use
publications or patents to measure output, two used in-
stead the quality of research as measured by the United
Kingdom Research Assessment Exercise and one [53]
used another quality index. Most of the remainder used
postgraduate (and, separately, undergraduate) student
numbers, usually in combination with a measure of re-
search funding. Undergraduate student numbers were
Table 4 Numbers of papers finding (dis-)economies of scope in
biomedical and health research – by type of research group
whose productivity is being analysed
Research
Teama
Departmentb University/Research
Institute
Total
Diseconomies of
scope
– 1 4 5
Economies of
scope
2 1 7 10
Evidence for both – 1 6 7
Total 2 3 17 22
aResearch Team, Sub-departmental laboratory/research unit
bUniversity department or research centre inside a bigger organisation. A
department is typically composed of a number of research teams
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used as a proxy for teaching output in studies of univer-
sities as multi-product firms with the products ‘teaching’
and ‘research’. Postgraduate student numbers were used
in a similar way as a proxy for graduate teaching, where
that was distinguished from undergraduate teaching.
However, as discussed earlier, PhD students can be seen
as an input to research activity as well as a proxy for the
output of graduate teaching. This makes those findings
problematic to interpret, e.g. a research group with more
PhD students that produces more publications is not ne-
cessarily being more productive per unit of research
labour if PhD students are considered in part to contrib-
ute to the research labour force.
Results by type of model used
All three of the types of econometric methods de-
scribed earlier were once again in evidence. Six of the
22 papers concerned with scope used a proxy vari-
ables approach, 11 used the cost function method,
and five used production functions (Table 5). Overall,
the studies were more likely to find positive econ-
omies of scope (10/22) than diseconomies of scope
(5/22), with seven studies finding evidence of both
economies and diseconomies.
Types of biomedical and health research
The likelihood of economies or diseconomies of scope
might be expected to differ according to the particular
types of biomedical and health research that are being
conducted. However, the studies we found in the litera-
ture are mostly at too high a level of aggregation to per-
mit distinct conclusions to be drawn about the presence
of economies or diseconomies of scope for different sub-
headings of research within ‘biomedical and health’, such
as basic research versus clinical research, or pharmaceut-
ical versus non-pharmaceutical.
Countries studied
As in the case of the literature about economies of scale,
the settings for the papers considering economies of
scope were mainly Europe (12/22), North America (8/22)
or both (1/22), with just one having a setting elsewhere,
namely in Bangladesh [19]. While in Europe the number
of articles suggesting economies and diseconomies of
scope is the same, in the case of North America no article
suggests purely diseconomies of scope. Five of the ar-
ticles with a focus in North America indicate positive
economies of scope and three show evidence for both
economies and diseconomies of scope. The focus of
studies looking at scope was never at a local, sub-
national level.
As mentioned above, only two studies analysed solely
economies of scope without mentioning economies of
scale. Cherchye et al. [54] assumed that a multi-output
production process is closely related with the concept of
economies of scope, since the process depends on the
joint use of input to produce a set of outputs. Using a
non-parametric characterisation of cost-efficient behav-
iour, their results suggest that, while the best universities
perform well in all areas in which they are involved, less
efficient universities can also perform very well in their
fields of specialisation. In the case of Glass et al. [55],
they compare more- and less-specialised universities to
explore which system yields relatively higher perform-
ance. Through the use of non-parametric DEA-based
models incorporating financial ratios, the findings indi-
cate that more-specialised university production results
in better performance on average than less-specialised
production.
Summary of findings about economies of scope
The effect on research outputs of varying the scope
of activities by a research group was less often re-
ported in empirical studies than the effect of scale.
Taken overall, the empirical literature more often sug-
gests the existence of positive economies of scope in
research than diseconomies, but the picture is mixed,
perhaps owing to the variety of settings focused on,
and the methods used, in the quantitative analyses.
The use of postgraduate student numbers and/or external
research funding won is problematic as they are inputs to
the research process as well as partial proxies for research
outputs. Economies of scope were predominantly tested at
the whole university/institute level.
Conclusions
Evidence on the presence of economies or diseconomies
of scale or scope when undertaking biomedical and
health research in publicly funded institutions is scat-
tered around a variety of literatures. We were able to
identify 60 papers up to November 2014 that presented
relevant evidence. A wide variety of analytical ap-
proaches were adopted, in an even wider variety of set-
tings. It is impractical in a single article to represent the
full diversity of the literature, but some overall conclu-
sions do emerge. The large majority of econometric
Table 5 Numbers of papers finding (dis-)economies of scope in
biomedical and health research
Proxy
variables
Multi-product
cost function
Multi-output
production function
Total
Diseconomies of
scope
1 3 1 5
Economies of
scope
4 5 1 10
Evidence for both 1 3 3 7
Total 6 11 5 22
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analyses relied on one or another of three main types of
model for investigating economies of scale and/or scope,
respectively using either proxy variables or multi-
product cost functions or multi-product production
functions. The type of model used did not noticeably
affect the conclusions – all three types of approach
found, in different papers, positive economies of scale,
or diseconomies, or evidence for both, and likewise for
economies of scope.
Challenges of measurement
There is no perfect measure for research outputs. The
most commonly used measures concern numbers of
publications and/or citations. A small number of studies
have referred to numbers of patents. A measure of ‘out-
put’ commonly found was student numbers, separately
identifying postgraduate and undergraduate students.
PhDs are arguably a proxy for part of the research out-
put of institutions of higher education and other publicly
funded institutes, but they are also an input to that
research, which makes interpreting the findings of
econometric studies that included them problematic.
Undergraduate student numbers are a proxy for teaching
output in studies that view institutions of higher educa-
tion as multi-product firms producing research, post-
graduate teaching and undergraduate teaching. Several
studies included levels of external research funding (e.g.
grants won) as a proxy for research output, but this
makes interpretation problematic as research funding is
necessarily strongly correlated with the cost and quantity
of the inputs to research.
Effects of scale and scope
The level of aggregation of the ‘research group’ being
studied affects the balance of likely conclusions about
the existence or otherwise of economies of scale. Where
the empirical evidence is clearest is at the level of uni-
versities or research institutes, where studies more often
point to the existence of positive economies of scale
than to diseconomies of scale in biomedical and health
research. However, both findings exist in the literature,
along with findings of inverse U-shaped relationships
which imply that, although economies of scale exist at
modest size ranges for organisations undertaking pub-
licly funded research, they eventually transform into dis-
economies as scale increases further.
At more disaggregated organisational levels, particu-
larly at the level of individual research units, laboratories
or projects, the numbers of studies are smaller and evi-
dence is very mixed. According to the particular study,
economies of scale are found, or diseconomies, or nei-
ther, or both. There is too little evidence to identify
where the turning points lie in those cases, and they vary
significantly according to the particular type of research
undertaken, but they are expressed in tens of staff rather
than hundreds.
Economies of scope have been less frequently studied in
the context of biomedical and health research than have
economies of scale. Overall, the literature more often sug-
gests the existence of positive economies of scope than
diseconomies; implying that organisations undertaking a
variety of research will be more productive than a collec-
tion of separate organisations each pursuing only one of
those research areas, but the picture is again mixed.
We found insufficient evidence to discern different de-
grees of (dis-)economies of scale or scope for different
types of biomedical and health research or different geo-
graphical regions.
The absence of predominant findings for or against
the existence of economies of scale or scope implies a
continuing need for case by case decisions when distrib-
uting research funding, rather than a general policy ei-
ther to concentrate funding in a few centres or to
disperse it across many.
We acknowledge a number of limitations of the study.
First, it was not feasible to compare the quality of the se-
lected articles. We tested the feasibility of formally and
systematically evaluating the papers by drawing on and
adapting two existing frameworks as suggested by
Gough [5]. However, the wide variety of methodologies
and approaches found in the literature hinder compari-
son of the quality of the articles. Therefore, it is recom-
mended for future studies to develop a publication
quality tool that reflects the main characteristics that an
article related to economies of scope and/or scale should
have.
Second, REA does not cover all available literature,
and could result in evidence being missed from the ana-
lysis. However, after considering the relative costs and
benefits of REA and Systematic Literature Review, we
selected REA as the more appropriate method for the
current analysis. Moreover, the limitation related to the
use of the REA is partially compensated by the fact
that (1) the search was done using a long list of data-
bases (EconLit, ASC, BSC, Cinhal, PubMed, Scopus,
and Web of Science), (2) it was supported by a pos-
terior ‘snowballing’ of the references included in the
papers identified, and (3) grey literature was included.
Third, given the scope of the project, we did not ex-
plore economies of scale and scope in private sector
R&D, where internal and external synergies are also tak-
ing place. Therefore, it is recommended for future stud-
ies to include economies of scale and scope related to
the private sector.
Despite the limitations, this literature review is the
first to be focused on the economies of scale and scope
in publicly funded biomedical and health research,
bringing light into a topic of high relevance for both
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funders and researchers. We found a large, disparate lit-
erature of relevance, containing studies of widely varying
types in terms not just of methodology and whether in-
vestigating scale or scope or both, but also of the level of
‘research group’ investigated, types of research within
and beyond ‘biomedical and health’, whether including
teaching in the study alongside research, geographic lo-
cation and vintage. What is clear is that there remains
plenty of room for further research into where and how
economies of scale or scope can be exploited and dis-
economies avoided. In particular, more work is needed
to understand how these economies or diseconomies
play out at lower levels of aggregation (below the whole
institute or university level) and to understand the role
of economies or diseconomies of scope rather than scale.
Furthermore, with public funding of research under
pressure in most economies, the incentive to identify
how best to organise biomedical and health research
most effectively and efficiently is clear and strong.
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